Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Marc Tessier-Lavigne. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Marc Tessier-Lavigne har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:DNLI / Denali Therapeutics Inc. | Director | 1 886 576 |
US:REGN / Regeneron Pharmaceuticals, Inc. | Director | 2 434 |
US:AGIO / Agios Pharmaceuticals, Inc. | Director | 48 875 |
US:JUNO / Juno Therapeutics, Inc. | Director | 12 000 |
US:PFE / Pfizer Inc. | Director | 29 100 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Marc Tessier-Lavigne. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp AGIO / Agios Pharmaceuticals, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i AGIO / Agios Pharmaceuticals, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2013-07-24 | AGIO | Tessier-Lavigne Marc | 55 555 | 18,0000 | 55 555 | 18,0000 | 999 990 | 331 | 49.5000 | 1 749 982 | 175,00 |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel AGIO / Agios Pharmaceuticals, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i AGIO / Agios Pharmaceuticals, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Marc Tessier-Lavigne som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 6 037 | 1 886 576 | 0,32 | ||||
2024-06-04 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 5 967 | 1 880 539 | 0,32 | ||||
2023-06-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 4 216 | 1 874 572 | 0,23 | ||||
2023-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
A - Award | 165 | 2 434 | 7,27 | ||||
2023-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
A - Award | 165 | 2 434 | 7,27 | ||||
2022-11-28 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −20 000 | 1 870 356 | −1,06 | 30,48 | −609 600 | 57 008 451 |
2022-11-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −11 252 | 1 890 356 | −0,59 | 30,33 | −341 273 | 57 334 497 |
2022-11-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −8 748 | 1 901 608 | −0,46 | 30,20 | −264 190 | 57 428 562 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 612 | 2 269 | −61,42 | 718,00 | −2 593 416 | 1 629 142 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 612 | 5 881 | 159,19 | 413,33 | 1 492 948 | 2 430 794 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 428 | 2 269 | −60,17 | 698,00 | −2 392 744 | 1 583 762 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 428 | 5 697 | 151,08 | 413,33 | 1 416 895 | 2 354 741 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 | 2 269 | −0,87 | 704,83 | −14 097 | 1 599 259 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 | 2 289 | −0,69 | 702,36 | −11 238 | 1 607 702 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −80 | 2 305 | −3,35 | 699,82 | −55 986 | 1 613 085 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −208 | 2 385 | −8,02 | 698,44 | −145 276 | 1 665 779 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −160 | 2 593 | −5,81 | 697,29 | −111 566 | 1 808 073 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −85 | 2 753 | −3,00 | 696,13 | −59 171 | 1 916 446 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −554 | 2 838 | −16,33 | 691,59 | −383 141 | 1 962 732 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −692 | 3 392 | −16,94 | 690,65 | −477 930 | 2 342 685 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 009 | 4 084 | −19,81 | 689,56 | −695 766 | 2 816 163 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −637 | 5 093 | −11,12 | 688,71 | −438 708 | 3 507 600 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −321 | 5 730 | −5,30 | 687,90 | −220 816 | 3 941 667 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 | 6 051 | −0,26 | 686,89 | −10 990 | 4 156 371 |
2022-10-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 798 | 6 067 | 167,39 | 413,33 | 1 569 827 | 2 507 673 |
2022-09-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 423 | 1 910 356 | −0,23 | 31,08 | −137 467 | 59 373 864 |
2022-09-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −15 577 | 1 914 779 | −0,81 | 30,74 | −478 837 | 58 860 306 |
2022-08-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −100 | 1 930 356 | −0,01 | 32,43 | −3 243 | 62 601 445 |
2022-08-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −19 900 | 1 930 456 | −1,02 | 31,61 | −629 039 | 61 021 714 |
2022-07-27 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −200 | 1 950 356 | −0,01 | 36,15 | −7 230 | 70 505 369 | |
2022-07-27 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −19 800 | 1 950 556 | −1,00 | 35,60 | −704 880 | 69 439 794 | |
2022-06-28 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −11 598 | 2 024 370 | −0,57 | 34,14 | −395 956 | 69 111 992 | |
2022-06-28 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −8 402 | 2 035 968 | −0,41 | 33,40 | −280 627 | 68 001 331 | |
2022-06-27 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
D - Sale to Issuer | −6 766 | 1 970 356 | −0,34 | 31,08 | −210 261 | 61 230 980 | |
2022-06-27 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
D - Sale to Issuer | −39 984 | 1 977 122 | −1,98 | 30,53 | −1 220 708 | 60 361 337 | |
2022-06-27 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
D - Sale to Issuer | −13 250 | 2 017 106 | −0,65 | 31,10 | −412 076 | 62 732 198 | |
2022-06-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 5 986 | 2 030 356 | 0,30 | ||||
2022-03-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −11 598 | 2 024 370 | −0,57 | 34,14 | −395 956 | 69 111 992 | |
2022-03-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −8 402 | 2 035 968 | −0,41 | 33,40 | −280 627 | 68 001 331 | |
2022-03-23 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −7 439 | 0 | −100,00 | |||
2022-03-23 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 439 | 2 269 | −76,63 | 690,00 | −5 132 910 | 1 565 610 |
2022-03-23 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 7 439 | 9 708 | 327,85 | 380,95 | 2 833 887 | 3 698 263 |
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −7 830 | 0 | −100,00 | |||
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 830 | 2 269 | −77,53 | 680,00 | −5 324 400 | 1 542 920 |
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 7 830 | 10 099 | 345,09 | 376,69 | 2 949 483 | 3 804 192 |
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 361 | 0 | −100,00 | |||
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 361 | 2 269 | −65,78 | 675,00 | −2 943 675 | 1 531 575 |
2022-03-18 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 361 | 6 630 | 192,20 | 374,12 | 1 631 537 | 2 480 416 |
2022-02-17 |
|
5 | DNLI |
Denali Therapeutics Inc.
Common Stock |
G - Gift | −200 000 | 2 044 370 | −8,91 | ||||
2022-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
A - Award | 2 707 | 2 707 | |||||
2022-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
A - Award | 191 | 2 269 | 9,19 | ||||
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −800 | 78 848 | −1,00 | 45,72 | −36 576 | 3 604 931 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −6 002 | 79 648 | −7,01 | 45,31 | −271 951 | 3 608 851 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −900 | 79 173 | −1,12 | 45,71 | −41 139 | 3 618 998 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −5 625 | 80 073 | −6,56 | 45,31 | −254 869 | 3 628 108 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 377 | 78 848 | −4,11 | 45,59 | −153 957 | 3 594 680 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 343 | 82 225 | −3,91 | 45,13 | −150 870 | 3 710 814 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −10 704 | 85 650 | −11,11 | 43,88 | −469 692 | 3 758 322 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −10 700 | 85 698 | −11,10 | 43,87 | −469 409 | 3 759 571 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −10 700 | 85 568 | −11,11 | 43,88 | −469 516 | 3 754 724 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 646 | 96 354 | −3,65 | 44,37 | −161 773 | 4 275 227 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 602 | 96 398 | −3,60 | 44,38 | −159 857 | 4 278 143 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 732 | 96 268 | −3,73 | 44,37 | −165 589 | 4 271 411 | |
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
G - Gift | 100 000 | 100 000 | |||||
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
G - Gift | 100 000 | 100 000 | |||||
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
G - Gift | 100 000 | 100 000 | |||||
2021-12-30 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
G - Gift | −300 000 | 2 244 370 | −11,79 | ||||
2021-12-10 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 784 | 0 | −100,00 | |||
2021-12-10 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 784 | 2 078 | −64,55 | 665,00 | −2 516 360 | 1 381 870 |
2021-12-10 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 784 | 5 862 | 182,10 | 371,40 | 1 405 378 | 2 177 147 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 250 | 0 | −100,00 | |||
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 250 | 0 | −100,00 | |||
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 250 | 8 500 | −33,33 | |||
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −139 | 2 078 | −6,27 | 652,26 | −90 664 | 1 355 396 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −249 | 2 217 | −10,10 | 651,54 | −162 233 | 1 444 464 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −56 | 2 466 | −2,22 | 650,33 | −36 418 | 1 603 714 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −124 | 2 522 | −4,69 | 649,35 | −80 519 | 1 637 661 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −381 | 2 646 | −12,59 | 648,25 | −246 983 | 1 715 270 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −425 | 3 027 | −12,31 | 647,39 | −275 141 | 1 959 650 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −354 | 3 452 | −9,30 | 646,24 | −228 769 | 2 230 820 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −61 | 3 806 | −1,58 | 645,21 | −39 358 | 2 455 669 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −844 | 3 867 | −17,92 | 644,52 | −543 975 | 2 492 359 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 549 | 4 711 | −24,74 | 643,33 | −996 518 | 3 030 728 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 645 | 6 260 | −20,81 | 642,54 | −1 056 978 | 4 022 300 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −952 | 7 905 | −10,75 | 641,56 | −610 765 | 5 071 532 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −981 | 8 857 | −9,97 | 640,61 | −628 438 | 5 673 883 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 260 | 9 838 | −11,35 | 639,45 | −805 707 | 6 290 909 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 098 | 11 098 | −15,90 | 638,46 | −1 339 489 | 7 085 629 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −816 | 13 196 | −5,82 | 637,71 | −520 371 | 8 415 221 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −816 | 14 012 | −5,50 | 636,64 | −519 498 | 8 920 600 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 250 | 14 828 | 40,18 | 273,67 | 1 163 098 | 4 057 979 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 250 | 14 828 | 40,18 | 273,67 | 1 163 098 | 4 057 979 |
2021-09-15 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 250 | 10 578 | 67,16 | 273,67 | 1 163 098 | 2 894 881 |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −27 245 | 0 | −100,00 | ||||
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −27 830 | 0 | −100,00 | ||||
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −39 303 | 7 862 | −83,33 | ||||
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −700 | 2 544 370 | −0,03 | 71,06 | −49 744 | 180 810 565 |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −93 678 | 2 545 070 | −3,55 | 70,34 | −6 589 779 | 179 032 949 |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 27 245 | 2 638 748 | 1,04 | 19,50 | 531 278 | 51 455 586 | |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 27 830 | 2 611 503 | 1,08 | 18,92 | 526 544 | 49 409 637 | |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 39 303 | 2 583 673 | 1,54 | 18,00 | 707 454 | 46 506 114 | |
2021-06-04 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 6 222 | 6 222 | |||||
2021-06-04 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 2 074 | 2 544 370 | 0,08 | ||||
2021-05-24 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −8 806 | 2 542 296 | −0,35 | 60,02 | −528 580 | 152 601 317 |
2021-05-24 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −37 957 | 2 551 102 | −1,47 | 60,13 | −2 282 468 | 153 405 417 |
2021-05-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −98 | 2 589 059 | 0,00 | 61,20 | −5 998 | 158 450 411 |
2021-05-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 139 | 2 589 157 | −0,12 | 60,08 | −188 591 | 155 556 553 |
2021-04-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −6 184 | 2 592 296 | −0,24 | 57,60 | −356 167 | 149 303 288 |
2021-04-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −29 593 | 2 598 480 | −1,13 | 56,91 | −1 684 019 | 147 869 103 |
2021-04-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −14 223 | 2 628 073 | −0,54 | 55,61 | −790 884 | 146 136 627 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 031 | 2 642 296 | −0,04 | 71,35 | −73 563 | 188 530 462 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 482 | 2 643 327 | −0,13 | 69,59 | −242 309 | 183 946 483 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −6 011 | 2 646 809 | −0,23 | 68,50 | −411 778 | 181 317 004 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −14 945 | 2 652 820 | −0,56 | 67,57 | −1 009 834 | 179 251 047 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −18 316 | 2 667 765 | −0,68 | 66,55 | −1 219 003 | 177 550 432 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −37 445 | 2 686 081 | −1,37 | 65,63 | −2 457 665 | 176 298 240 |
2021-03-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −18 770 | 2 723 526 | −0,68 | 64,36 | −1 208 056 | 175 288 857 |
2021-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
A - Award | 3 613 | 3 613 | |||||
2021-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
A - Award | 248 | 2 078 | 13,55 | ||||
2020-06-18 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −400 000 | 2 739 043 | −12,74 | 26,10 | −10 440 000 | 71 489 022 | |
2020-06-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 3 253 | 3 253 | |||||
2020-06-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 15 183 | 15 183 | |||||
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −15 000 | 0 | −100,00 | ||||
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −100 | 1 830 | −5,18 | 566,01 | −56 601 | 1 035 798 | |
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −900 | 1 930 | −31,80 | 565,35 | −508 815 | 1 091 126 | |
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 600 | 2 830 | −69,99 | 564,45 | −3 725 370 | 1 597 394 | |
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 375 | 9 430 | −40,34 | 563,45 | −3 591 994 | 5 313 334 | |
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 025 | 15 805 | −6,09 | 562,65 | −576 716 | 8 892 683 | |
2020-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 15 000 | 16 830 | 819,67 | 177,82 | 2 667 300 | 2 992 711 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −5 000 | 0 | −100,00 | ||||
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −9 279 | 0 | −100,00 | ||||
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −7 842 | 1 830 | −81,08 | 400,16 | −3 138 055 | 732 293 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −800 | 9 672 | −7,64 | 399,41 | −319 528 | 3 863 094 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −637 | 10 472 | −5,73 | 398,71 | −253 978 | 4 175 291 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 9 279 | 11 109 | 507,05 | 50,91 | 472 394 | 565 559 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 000 | 1 830 | −73,21 | 400,03 | −2 000 150 | 732 055 | |
2020-02-14 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 5 000 | 6 830 | 273,22 | 57,11 | 285 550 | 390 061 | |
2020-01-06 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy) |
A - Award | 4 361 | 4 361 | |||||
2020-01-06 |
|
4 | REGN |
REGENERON PHARMACEUTICALS, INC.
Common Stock |
A - Award | 320 | 1 830 | 21,19 | ||||
2019-05-31 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 27 245 | 27 245 | |||||
2019-01-04 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 3 784 | 3 784 | |||||
2019-01-04 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
A - Award | 323 | 1 510 | 27,21 | ||||
2018-06-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 27 830 | 27 830 | |||||
2018-01-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 7 439 | 7 439 | |||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Preferred Stock |
C - Conversion | −25 000 | 0 | −100,00 | ||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 25 000 | 3 139 043 | 0,80 | ||||
2017-12-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 47 165 | 47 165 | |||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
6 228 086 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
6 228 086 | ||||||||
2017-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 7 830 | 7 830 | |||||
2016-06-23 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 8 500 | 48 875 | 21,05 | ||||
2016-06-21 |
|
4 | JUNO |
Juno Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 12 000 | 12 000 | |||||
2016-01-06 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 9 212 | 9 212 | |||||
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −5 000 | 5 000 | −50,00 | ||||
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −500 | 1 187 | −29,64 | 595,44 | −297 720 | 706 787 | |
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 000 | 1 687 | −54,24 | 593,64 | −1 187 280 | 1 001 471 | |
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 000 | 3 687 | −21,34 | 590,17 | −590 170 | 2 175 957 | |
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 500 | 4 687 | −24,24 | 584,07 | −876 105 | 2 737 536 | |
2015-08-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 000 | 6 187 | 421,23 | 57,11 | 285 550 | 353 340 | |
2015-06-25 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 11 262 | 40 375 | 38,68 | ||||
2015-06-16 |
|
4 | JUNO |
Juno Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 12 000 | 12 000 | |||||
2015-04-24 |
|
4 | PFE |
PFIZER INC
Phantom Stock Units |
A - Award | 4 596 | 29 100 | 18,75 | 35,36 | 162 500 | 1 028 975 | |
2015-02-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 000 | 9 279 | −24,43 | ||||
2015-02-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −300 | 1 187 | −20,17 | 424,44 | −127 332 | 503 810 | |
2015-02-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 100 | 1 487 | −42,52 | 423,64 | −466 004 | 629 953 | |
2015-02-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 600 | 2 587 | −38,21 | 420,33 | −672 528 | 1 087 394 | |
2015-02-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 000 | 4 187 | 252,74 | 50,91 | 152 730 | 213 160 | |
2015-01-05 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 10 838 | 10 838 | |||||
2014-12-23 |
|
4 | JUNO |
Juno Therapeutics, Inc.
Series A-2 Preferred Stock |
C - Conversion | −175 000 | 0 | −100,00 | ||||
2014-12-23 |
|
4 | JUNO |
Juno Therapeutics, Inc.
Common Stock |
C - Conversion | 175 000 | 250 000 | 233,33 | ||||
2014-12-18 | 3 | JUNO |
Juno Therapeutics, Inc.
Common Stock |
150 000 | ||||||||
2014-12-18 | 3 | JUNO |
Juno Therapeutics, Inc.
Common Stock |
150 000 | ||||||||
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 000 | 12 279 | −19,63 | ||||
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 000 | 1 187 | −71,65 | 352,20 | −1 056 600 | 418 061 | |
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 000 | 4 187 | 252,74 | 50,91 | 152 730 | 213 160 | |
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 387 | 15 279 | −8,32 | ||||
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
F - Taxes | −200 | 1 187 | −14,42 | 351,62 | −70 324 | 417 373 | |
2014-08-27 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 387 | 1 387 | 50,91 | 70 612 | 70 612 | ||
2014-06-05 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 14 000 | 29 113 | 92,64 | ||||
2014-04-28 |
|
4 | PFE |
PFIZER INC
Phantom Stock Units |
A - Award | 5 291 | 23 671 | 28,79 | 30,71 | 162 500 | 726 932 | |
2014-04-03 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
P - Purchase | 55 555 | 101 009 | 122,22 | 18,00 | 999 990 | 1 818 162 | |
2014-01-06 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 12 750 | 12 750 | |||||
2013-12-06 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock (right to buy) |
A - Award | 10 750 | 15 113 | 246,39 | ||||
2013-07-23 | 3 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
45 454 | ||||||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −300 | 10 000 | −2,91 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −500 | 10 300 | −4,63 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 700 | 10 800 | −13,60 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 700 | 10 800 | −13,60 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −800 | 14 200 | −5,33 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −8 334 | 16 666 | −33,34 | ||||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −300 | 0 | −100,00 | 264,17 | −79 251 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 300 | 300 | 57,11 | 17 133 | 17 133 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −500 | 0 | −100,00 | 263,50 | −131 750 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 500 | 500 | 57,11 | 28 555 | 28 555 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 700 | 0 | −100,00 | 262,49 | −446 233 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 700 | 1 700 | 57,11 | 97 087 | 97 087 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 700 | 1 700 | 57,11 | 97 087 | 97 087 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 700 | 0 | −100,00 | 261,53 | −444 601 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −800 | 0 | −100,00 | 260,75 | −208 600 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 800 | 800 | 57,11 | 45 688 | 45 688 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
S - Sale | −8 334 | 0 | −100,00 | 260,20 | −2 168 507 | ||
2013-05-08 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 334 | 8 334 | 50,91 | 424 284 | 424 284 | ||
2013-04-26 |
|
4 | PFE |
PFIZER INC
Phantom Stock Units |
A - Award | 4 544 | 17 794 | 34,29 | 30,26 | 137 500 | 538 436 | |
2013-01-03 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 15 000 | 15 000 | |||||
2012-04-27 |
|
4 | PFE |
PFIZER INC
Phantom Stock Units |
A - Award | 5 963 | 12 776 | 87,51 | 23,06 | 137 500 | 294 619 | |
2012-01-04 |
|
4 | REGN |
REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 15 000 | 15 000 |